The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors-Reference-Cited by-同舟云学术

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors

Published:2011-02 Issue:2 Volume:6 Page:387-392
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kancha Rama Krishna,Peschel Christian,Duyster Justus

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007

3. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib;Kobayashi;N Engl J Med,2005

4. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants;Greulich;PLoS Med,2005

5. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy;Kancha;Clin Cancer Res,2009

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current management of uncommon EGFR mutations in non-small cell lung cancer;Current Problems in Cancer;2024-04

2. Genomic features of lung cancer patients in Indonesia’s national cancer center;BMC Pulmonary Medicine;2024-01-20

3. Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib;Respiratory Medicine Case Reports;2023-12

4. Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC;Diagnostics;2022-09-29

5. Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment : integrated computational analysis and in vitro study;Scientific Reports;2022-08-17